124 related articles for article (PubMed ID: 37865290)
41. BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
Padilla N; Moles-Fernández A; Riera C; Montalban G; Özkan S; Ootes L; Bonache S; Díez O; Gutiérrez-Enríquez S; de la Cruz X
Hum Mutat; 2019 Sep; 40(9):1593-1611. PubMed ID: 31112341
[TBL] [Abstract][Full Text] [Related]
42. Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants.
Shulman C; Liang E; Kamura M; Udwan K; Yao T; Cattran D; Reich H; Hladunewich M; Pei Y; Savige J; Paterson AD; Suico MA; Kai H; Barua M
Kidney Med; 2021; 3(2):257-266. PubMed ID: 33851121
[TBL] [Abstract][Full Text] [Related]
43. Evidence for pathogenicity of variant ATM Val1729Leu in a family with ataxia telangiectasia.
Shalash AS; Rösler TW; Salama M; Pendziwiat M; Müller SH; Hopfner F; Höglinger GU; Kuhlenbäumer G
Neurogenetics; 2021 May; 22(2):143-147. PubMed ID: 33779842
[TBL] [Abstract][Full Text] [Related]
44. Characterization of New
Parenti S; Rabacchi C; Marino M; Tenedini E; Artuso L; Castellano S; Carretta C; Mallia S; Cortesi L; Toss A; Barbieri E; Manfredini R; Luppi M; Trenti T; Tagliafico E
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33494414
[TBL] [Abstract][Full Text] [Related]
45. ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.
Arts HH; Lynch L; Grafodatskaya D; Eng B; Malloy L; Duck J; White R; Woodside C; Bell K; Zbuk KM; McCready E
Cancer Genet; 2020 Jan; 240():1-4. PubMed ID: 31671381
[TBL] [Abstract][Full Text] [Related]
46. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
[TBL] [Abstract][Full Text] [Related]
47. The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
Moslemi M; Moradi Y; Dehghanbanadaki H; Afkhami H; Khaledi M; Sedighimehr N; Fathi J; Sohrabi E
BMC Cancer; 2021 Jan; 21(1):27. PubMed ID: 33402103
[TBL] [Abstract][Full Text] [Related]
48. Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Renault AL; Dowty JG; Steen JA; Li S; Winship IM; Giles GG; Hopper JL; Southey MC; Nguyen-Dumont T
Breast Cancer Res; 2022 Apr; 24(1):24. PubMed ID: 35365198
[TBL] [Abstract][Full Text] [Related]
49. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
[TBL] [Abstract][Full Text] [Related]
50. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Pejaver V; Byrne AB; Feng BJ; Pagel KA; Mooney SD; Karchin R; O'Donnell-Luria A; Harrison SM; Tavtigian SV; Greenblatt MS; Biesecker LG; Radivojac P; Brenner SE;
Am J Hum Genet; 2022 Dec; 109(12):2163-2177. PubMed ID: 36413997
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of in silico predictors on short nucleotide variants in
Tamana S; Xenophontos M; Minaidou A; Stephanou C; Harteveld CL; Bento C; Traeger-Synodinos J; Fylaktou I; Yasin NM; Abdul Hamid FS; Esa E; Halim-Fikri H; Zilfalil BA; Kakouri AC; ; Kleanthous M; Kountouris P
Elife; 2022 Dec; 11():. PubMed ID: 36453528
[TBL] [Abstract][Full Text] [Related]
52. First international workshop of the ATM and cancer risk group (4-5 December 2019).
Lesueur F; Easton DF; Renault AL; Tavtigian SV; Bernstein JL; Kote-Jarai Z; Eeles RA; Plaseska-Karanfia D; Feliubadaló L; ; Arun B; Herold N; Versmold B; Schmutzler RK; ; Nguyen-Dumont T; Southey MC; Dorling L; Dunning AM; Ghiorzo P; Dalmasso BS; Cavaciuti E; Le Gal D; Roberts NJ; Dominguez-Valentin M; Rookus M; Taylor AMR; Goldstein AM; Goldgar DE; ; Stoppa-Lyonnet D; Andrieu N
Fam Cancer; 2022 Apr; 21(2):211-227. PubMed ID: 34125377
[TBL] [Abstract][Full Text] [Related]
53. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer.
Izatt L; Greenman J; Hodgson S; Ellis D; Watts S; Scott G; Jacobs C; Liebmann R; Zvelebil MJ; Mathew C; Solomon E
Genes Chromosomes Cancer; 1999 Dec; 26(4):286-94. PubMed ID: 10534763
[TBL] [Abstract][Full Text] [Related]
54. Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.
Pitter KL; Casey DL; Lu YC; Hannum M; Zhang Z; Song X; Pecorari I; McMillan B; Ma J; Samstein RM; Pei IX; Khan AJ; Braunstein LZ; Morris LGT; Barker CA; Rimner A; Alektiar KM; Romesser PB; Crane CH; Yahalom J; Zelefsky MJ; Scher HI; Bernstein JL; Mandelker DL; Weigelt B; Reis-Filho JS; Lee NY; Powell SN; Chan TA; Riaz N; Setton J
J Natl Cancer Inst; 2021 Mar; 113(3):266-273. PubMed ID: 32726432
[TBL] [Abstract][Full Text] [Related]
55. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
Lyra PCM; Nepomuceno TC; de Souza MLM; Machado GF; Veloso MF; Henriques TB; Dos Santos DZ; Ribeiro IG; Ribeiro RS; Rangel LBA; Richardson M; Iversen ES; Goldgar D; Couch FJ; Carvalho MA; Monteiro ANA
Genet Med; 2021 Feb; 23(2):306-315. PubMed ID: 33087888
[TBL] [Abstract][Full Text] [Related]
56. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
Bernstein JL; Haile RW; Stovall M; Boice JD; Shore RE; Langholz B; Thomas DC; Bernstein L; Lynch CF; Olsen JH; Malone KE; Mellemkjaer L; Borresen-Dale AL; Rosenstein BS; Teraoka SN; Diep AT; Smith SA; Capanu M; Reiner AS; Liang X; Gatti RA; Concannon P;
J Natl Cancer Inst; 2010 Apr; 102(7):475-83. PubMed ID: 20305132
[TBL] [Abstract][Full Text] [Related]
57. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
[TBL] [Abstract][Full Text] [Related]
58. Breast Irradiation Is Well Tolerated in Carriers of a Pathogenic ATM Variant.
Zureick AH; Zakalik D; Quinn TJ; Rangarajan TS; Grzywacz VP; Rotenbakh LR; Chen PY; Dilworth JT
Pract Radiat Oncol; 2024; 14(1):e29-e39. PubMed ID: 37742832
[TBL] [Abstract][Full Text] [Related]
59. Germline likely pathogenic variants in ataxia-telangiectasia-mutated gene in an Iranian family with hereditary diffuse gastric cancer without
Kheirollahi M; Saneipour M; Moridnia A
J Cancer Res Ther; 2021; 17(6):1434-1437. PubMed ID: 34916374
[TBL] [Abstract][Full Text] [Related]
60. Informing variant assessment using structured evidence from prior classifications (PS1, PM5, and PVS1 sequence variant interpretation criteria).
Bhat V; Adzhubei IA; Fife JD; Lebo M; Cassa CA
Genet Med; 2023 Jan; 25(1):16-26. PubMed ID: 36305854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
